Related Experiment Video
Updated: Aug 19, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.9K
Long-Acting Insulin-Zwitterionic Polymer Conjugate Mitigates Hypoglycemia
Zhipeng Zeng1, Wangmeng Hou2, Zhitao Hu2
1Laboratory of Biomaterials and Translational Medicine Center for Nanomedicine The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510630, P. R. China.
Chemistry (Weinheim an Der Bergstrasse, Germany)
|November 29, 2022
Summary
Researchers developed a new insulin-zwitterionic polymer conjugate (INS-PMPC) for diabetes treatment. This stable conjugate offers over 20 hours of glycemic control with reduced hypoglycemia risk in diabetic mice.
Area of Science:
- Biomaterials Science
- Polymer Chemistry
- Endocrinology
Background:
- Insulin is crucial for managing type 1 and type 2 diabetes.
- Current insulin formulations suffer from short half-life and poor stability.
- Zwitterionic polymers offer antifouling and low immunogenicity properties.
Purpose of the Study:
- To synthesize and characterize a novel insulin-zwitterionic polymer conjugate (INS-PMPC).
- To evaluate the stability, pharmacokinetics, and glycemic control of INS-PMPC in a diabetic mouse model.
- To assess the safety profile, specifically the incidence of hypoglycemia.
Main Methods:
- Grafting-from strategy using controlled radical polymerization to create INS-PMPC.
- Assessment of conjugate stability under mechanical agitation.
- In vivo studies in diabetic mice to monitor blood glucose levels and pharmacokinetics after subcutaneous injection.
- Evaluation of hypoglycemia incidence.
Main Results:
- The synthesized INS-PMPC conjugate demonstrated excellent stability.
- A single subcutaneous injection of INS-PMPC provided over 20 hours of glycemic control in diabetic mice.
- The INS-PMPC conjugate significantly reduced the incidence of hypoglycemia compared to conventional insulin.
Conclusions:
- INS-PMPC represents a promising advancement in insulin therapy for diabetes.
- The zwitterionic polymer conjugation enhances insulin stability and prolongs its action.
- This novel conjugate offers improved glycemic management with a reduced risk of hypoglycemia.
More Related Videos
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
250
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
250
01:24Glucagon-like Receptor Agonists
383
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
383
01:06Oral Hypoglycemic Agents: Glinides
215
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
215
01:16Insulin: Dosing Regimen and Adverse Effects
226
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
226
01:25Insulin: Biosynthesis, Chemistry, and Preparation
474
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
474
01:23Dipeptidyl Peptidase 4 Inhibitors
230
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
230